GLS and sarcoma: Given that GLS expression supports sarcomagenesis, we evaluated GLS inhibitors and determined that Telaglenastat (CB-839; a small molecule inhibitor in phase I and II clinical trials32) effectively blocks GLS activity and sarcoma growth (Figs. 5–7).